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Absorb BVS showed similar incidence of 1-year MACE when compared to non-
diabetic patients.
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Background: Bioresorbable vascular scaffolds represent an exciting advance in
percutaneous coronary intervention (PCI), providing an initial coronary scaffold
which are eventually resorbed by the body. The DESolve Nx Bioresorbable
Coronary Scaffold System (BCSS) is a novel drug eluting bioresorbable scaffold
that combines a PLLA-based scaffold coated with a biodegradable polylactide-
based polymer and the drug Novolimus, a macrocyclic lactone mTOR inhibitor
which has demonstrated potent anti-proliferative properties in previous clinical
trials using Elixir's metallic Novolimus-Eluting (NE) coronary stents. The
DESolve NX study is a prospective, multicenter evaluation of the safety and
efﬁcacy of the DESolve Nx NEBCSS in patients with single de novo native
coronary artery lesions through clinical endpoints and multiple imaging
modalities.
Methods: 126 patients with single, de novo coronary artery lesions were enrolled in
this prospective, multi-centre, single-arm study. Those patients receiving the study
device are being analysed for multiple clinical endpoints including: Major Adverse
Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, or
clinically-indicated target lesion revascularization (CI-TLR); Clinically-indicated
Target Lesion and Target Vessel Revascularization, (CI-TVR) and Stent Thrombosis
assessed at 1, 6 and 12 months and annually to 5 years. All patients underwent
angiographic assessment at 6 months and a subset of patients underwent IVUS and
OCT assessment at 6 months and MSCT at 12 months.
Results: At baseline, the patient population had a mean age 62 years, 32% were
females, 21% were diabetic. Pre-procedure mean lesion length was 11.2 mm, RVD
was 3.06 mm. Serial QCA imaging at 6 months demonstrated low mean in-scaffold
late lumen loss (0.21mm.IVUS and OCT imaging indicated early vessel restoration at
6 months. Clinical events remained low (MACE ¼ 3.25% at 6 months) with no reports
of deﬁnite stent thrombosis.
Conclusions: The DESolve Nx NEBCSS demonstrated safety and efﬁcacy in
treating de novo coronary artery lesions with low clinical event rate and evidence of
low late lumen loss at 6 months. A ﬁrst report of results through 12 months will be
presented.TCT-38
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Background: In order to assess the intermediate term safety, clinical performance and
the bioabsorption process of the Paclitaxel-Eluting Bioabsorbable MagnesiumJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrScaffold (DREAMS) 3-year clinical data of cohort 1 and multi-modality imaging
outcomes are reported.
Methods: Forty-six subjects were enrolled in the ﬁrst-in-man BIOSOLVE-I study in
two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months;
angiographic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12-
month. A subgroup of patients underwent OCT and vasomotion testing. The
primary endpoint is Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12-
month for cohort 2. For some patients also 18-month and 24-month imaging data
are available.
Results: TLF rate at 24-month was 6.8% including 2 TLRs and 1 peri-procedural
MI occurring at the 12-month follow-up angiography; no events emerged from
12- to 24-month. No cardiac death or scaffold thrombosis was observed. 36-
month clinical data of Cohort 1 will be available upon presentation. Vasocon-
striction after acetylcholine at 6-month (Delta¼-10.04%; p¼0.0008 versus
baseline) followed by vasodilatation after nitroglycerine (Delta¼8.69%;
p<0.0001 versus baseline) demonstrates the uncaging aspect of the absorption
process with no further change at the 12-month follow-up. Six-month virtual
histology (VH) data showed a signiﬁcant decrease in the dense calcium by
39.5% (p¼0.0015) remaining stable from 6- to 12-month follow-up. This
decrease is interpreted as a surrogate assessment for the bioabsorption process of
the scaffold material. Preliminary echogenicity data using the decrease in
intensity of the ultrasound signal to quantify the change in strut structure
demonstrate a relatively large decrease of hyperechogenicity (28.5%) in the ﬁrst
6-month, followed by lower decrease (18.4%) in the 6 months thereafter, with
indications that the hyperechogenicity at 18-month returns to the values seen pre-
implantation.
Conclusions: DREAMS shows excellent safety and efﬁcacy data with no death and
no scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality
imaging documented the absorption process and the uncaging aspect of this device
already at 6 months.TCT-39
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Background: ReZolve is a novel scaffold incorporating a unique slide & lock
expansion technology and a proprietary bioresorbable stent material that is
a polycarbonate co-polymer of tyrosine analogs. The aim of this study was to
evaluate, for the ﬁrst time, the safety and performance of the ReZolve siroli-
mus-eluting bioresorbable coronary scaffold in non-complex human coronary
lesions.
Methods: The RESTORE trial is a prospective, multi-center and multi-national trial
enrolling patients with single, de novo lesions in native coronary arteries with an
average reference diameter between 2.9 mm to 3.3 mm and lesion length up to 12
mm. The primary study endpoint was freedom from ischemic-driven target lesion
revascularization (TLR) at 6-months and 12-month in-scaffold late loss. Serial
IVUS evaluation (post procedure and at 12 months) was also performed in
a subgroup of patients. All imaging analyses were performed by independent core
labs.
Results: A total of 26 patients were enrolled in this trial and the device was
successfully implanted in 22 cases. Most patients were male (76%) and 36% of all
patients had diabetes. Mean reference vessel diameter and lesion length were 2.72 mm
and 11.1 mm, respectively. Acute recoil was minimal at 3.8%  6.7%. Through 6
months post-implant there were 2 focal in-scaffold TLRs. The 12-month QCA eval-
uation was completed for the ﬁrst 8 patients and resulted in a late loss of 0.20  0.19
mm. Of note, the mean stent diameter at implant in this initial group of patients was
2.94mm and remained constant over the 12-month follow-up period. The QCA and
safety data for the remaining patients as well as full IVUS assessment will be available
at the time of the meeting.
Conclusions: In this preliminary assessment, the ReZolve scaffold showed
excellent acute performance with minimal acute recoil. Complete 12-month
QCA and IVUS data is required to conﬁrm the performance of this novel
device.acts/ORAL/Bioabsorbable Vascular Scaffolds B13
